Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 3-Year EBITDA Growth Rate is 77.30% as of Mar. 2026, which is at its 10-year median of 77.30. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,125 Biotechnology companies, Psyence Biomedical ranks better than 95.73% on this metric.
During the past 12 months, Psyence Biomedical's average EBITDA Per Share Growth Rate was -137.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 77.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Psyence Biomedical was 77.30% per year. The lowest was 77.30% per year. And the median was 77.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Psyence Biomedical 3-Year EBITDA Growth Rate Related Terms
PBM vs NRSN, PLUR, CALC: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Psyence Biomedical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 77.30% mean?
Psyence Biomedical (PBM) has a 3-Year EBITDA Growth Rate of 77.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Psyence Biomedical and its competitors. This is near median its historical median of 77.30. Over the past decade, Psyence Biomedical's 3-Year EBITDA Growth Rate has ranged from 77.30 to 77.30. According to the industry distribution chart, Psyence Biomedical ranks #48 out of 1125 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Psyence Biomedical's 3-Year EBITDA Growth Rate too high?
Psyence Biomedical's current 3-Year EBITDA Growth Rate of 77.30% is near median its 10-year median of 77.30. Over the past 10 years, this metric has ranged from a low of 77.30 to a high of 77.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Psyence Biomedical's value of 77.30% is 425.9% above this industry median. Based on the distribution chart, Psyence Biomedical ranks #48 out of 1125 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's 3-Year EBITDA Growth Rate compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #48 out of 1125 companies for 3-Year EBITDA Growth Rate. This places Psyence Biomedical in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Psyence Biomedical's value of 77.30% is 425.9% above this benchmark. Historically, Psyence Biomedical's own 3-Year EBITDA Growth Rate has ranged from 77.30 to 77.30 over the past decade. While the company's 10-year median is 77.30 vs. the industry median of 14.70, Psyence Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,125 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Psyence Biomedical's current 3-Year EBITDA Growth Rate of 77.30% is 425.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Psyence Biomedical and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current 3-Year EBITDA Growth Rate is 77.30%, which is near median its own 10-year median of 77.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current 3-Year EBITDA Growth Rate of 77.30%. The current 3-Year EBITDA Growth Rate is 77.30%, which is near median its 10-year median of 77.30 and 425.9% above the Biotechnology industry median of 14.70. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current 3-Year EBITDA Growth Rate is 77.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
